ATNM

Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Actinium Pharmaceuticals Inc revenue for the last quarter amounts to 90.00K USD, decreased % YoY.

Actinium Pharmaceuticals Inc. EPS for the last quarter amounts to -0.16 USD, decreased -56.76 % YoY.

Actinium Pharmaceuticals Inc (ATNM) has 37 emplpoyees as of December 15 2025.

Today ATNM has the market capitalization of 47.11M USD.